
Invitae Corporation NVTA
Quarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Operating Expenses 2011-2026 | NVTA
Annual Operating Expenses Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 343 M | 190 M | 139 M | 97.4 M | 81.3 M | 43.3 M | 24.2 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 343 M | 24.2 M | 131 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Burning Rock Biotech Limited
BNR
|
726 M | $ 16.1 | -0.62 % | $ 173 M | ||
|
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
1.99 B | $ 115.14 | -0.29 % | $ 35 B | ||
|
CareDx, Inc
CDNA
|
411 M | $ 18.04 | -1.47 % | $ 961 M | ||
|
Co-Diagnostics
CODX
|
50.6 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 167.07 | -3.92 % | $ 8.28 B | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 25.22 | 1.51 % | $ 701 M | ||
|
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
Danaher Corporation
DHR
|
6.71 B | $ 192.03 | 0.48 % | $ 137 B | ||
|
DexCom
DXCM
|
1.89 B | $ 62.94 | 1.16 % | $ 24.6 B | ||
|
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M | ||
|
Fulgent Genetics
FLGT
|
181 M | $ 16.53 | -1.72 % | $ 500 M | ||
|
Guardant Health
GH
|
226 M | $ 90.55 | -3.5 % | $ 11.4 B | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 110.43 | -3.29 % | $ 9.11 B | ||
|
Interpace Biosciences
IDXG
|
20 M | $ 1.92 | -1.92 % | $ 8.49 M | ||
|
Illumina
ILMN
|
3.69 B | $ 126.99 | -0.31 % | $ 20.2 B | ||
|
IQVIA Holdings
IQV
|
2.94 B | $ 169.79 | -2.0 % | $ 29.2 B | ||
|
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 274.64 | 0.34 % | $ 22.9 B | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 76.45 | 0.46 % | $ 5.16 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | ||
|
Medpace Holdings
MEDP
|
118 M | $ 496.04 | -0.46 % | $ 14.3 B | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
Mettler-Toledo International
MTD
|
1.01 B | $ 1 262.72 | 0.22 % | $ 26 B | ||
|
Myriad Genetics
MYGN
|
964 M | $ 4.78 | 0.53 % | $ 443 M | ||
|
ENDRA Life Sciences
NDRA
|
5.76 M | $ 4.56 | -2.72 % | $ 3.59 M | ||
|
NeoGenomics
NEO
|
430 M | $ 7.98 | -0.31 % | $ 1.02 B | ||
|
Neogen Corporation
NEOG
|
1.48 B | $ 9.44 | 0.32 % | $ 2.05 B | ||
|
Biodesix
BDSX
|
106 M | $ 15.9 | 5.48 % | $ 2.06 B | ||
|
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | ||
|
National Research Corporation
NRC
|
38.5 M | $ 17.56 | 2.33 % | $ 393 M | ||
|
Natera
NTRA
|
258 M | $ 204.71 | -1.57 % | $ 20.1 B | ||
|
Pacific Biosciences of California
PACB
|
600 M | $ 1.41 | 4.85 % | $ 423 M | ||
|
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 27.12 | 0.04 % | $ 20 B | ||
|
Precipio
PRPO
|
11.9 M | $ 26.16 | 2.99 % | $ 42 M | ||
|
Personalis
PSNL
|
44.5 M | $ 6.58 | - | $ 390 M | ||
|
RadNet
RDNT
|
1.98 B | $ 54.92 | 0.23 % | $ 4.13 B | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
Senseonics Holdings
SENS
|
61.8 M | $ 6.88 | -0.29 % | $ 287 M | ||
|
Sotera Health Company
SHC
|
309 M | $ 14.89 | -0.47 % | $ 4.23 B | ||
|
Soleno Therapeutics
SLNO
|
181 M | $ 52.28 | 32.38 % | $ 2.66 B |